BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-60@catalystbrief.girapphe.com
DTSTAMP:20261117T061552Z
LAST-MODIFIED:20261117T061552Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Clarity Pharmaceuticals Ltd — 64Cu-SAR-bisPSMA [Dec 2026
 ]
DESCRIPTION:Phase 3 primary completion: 64Cu-SAR-bisPSMA Positron Emission 
 Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of
  Prostate Cancer.\nSource: https://clinicaltrials.gov/study/NCT06970847\nh
 ttps://catalystbrief.girapphe.com/e/60?lang=en\nNot investment advice. Dat
 es may change.
URL:https://catalystbrief.girapphe.com/e/60?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
